NRC Health (NRC) vs Nuvalent Inc (NUVL)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| NRC | NUVL | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Health Information Services | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq GS | Nasdaq GM |
| Country | United States | United States |
| Theme | healthtech-software | oncology |
| Price and returns | ||
| Last close | $22.45 | $123.96 |
| Return · 1 week | +9.67% | 0.00% |
| Return · 1 month | +11.91% | 0.00% |
| Return · 3 months | +0.49% | 0.00% |
| Return · year to date | +25.66% | +22.93% |
| Return · 1 year | +100.10% | +26.87% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −5.19% | −0.02% |
| 52-week high | $23.68 | $123.99 |
| 52-week low | $11.32 | $87.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $497.03M | $9.79B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $2.46M | $149.69M |
| Employees | 357 | 234 |
| Valuation | ||
| Price to earnings · trailing | 83.96× | n/a (negative earnings) |
| Price to earnings · forward | 19.19× | n/a (negative forward earnings) |
| Price to sales | 3.19× | — |
| Price to book | 68.07× | 8.33× |
| Enterprise value to EBITDA | 19.98× | — |
| Enterprise value to revenue | 3.81× | — |
| PEG ratio | 1.32 | — |
| Earnings per share · trailing | 0.24 | -6.06 |
| Profitability | ||
| Gross margin | 61.75% | — |
| Operating margin | −0.22% | 0.00% |
| Profit margin | 3.92% | — |
| Return on equity | 42.03% | −41.19% |
| Return on assets | 8.13% | −22.51% |
| Growth | ||
| Revenue growth | +4.00% | — |
| Balance sheet and payout | ||
| Debt / equity (%) | 1,381.07 | — |
| Current ratio | 0.65 | 16.14 |
| Dividend yield | 3.18% | — |
| Payout ratio | 250.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 61.99 | — |
| ADX · 14 | 11.44 | — |
| 50-day average | $21.12 | — |
| 200-day average | $19.12 | — |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 3.49% | — |
The full NRC analysis
Everything this table leaves out for NRC Health: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NRC argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NRC analysisThe full NUVL analysis
Everything this table leaves out for Nuvalent Inc: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the NUVL argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full NUVL analysis